Overview of the Inflation Reduction Act’s Impact on Drug Pricing and Medicare Part D

Winnie McBride and Jay Warmuth discussed provisions in the Inflation Reduction Act (IRA) that are focused on lowering prescription drug costs for Medicare beneficiaries and the federal government. They covered the Part D benefit redesign, the requirement for the secretary of Health and Human Services to negotiate certain drug prices with manufacturers, and the payment rebates by drug manufacturers to Medicare for drug prices that outpace inflation.